The development of new radiopharmaceuticals able to target the PSMA protein, e.g., [68Ga]Ga-PSMA-11, [18F]PSMA-1007, and [18F]DCFPyL, has significantly contributed to improved PCa diagnosis, treatment, decision-making, and patient care management [6]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.